Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model - PubMed (original) (raw)

. 2003 Nov 15;63(22):7853-60.

Affiliations

• PMID: 14633713

Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model

Takefumi Satoh et al. Cancer Res. 2003.

Abstract

We investigated the efficacy of intratumoral injection of macrophages transduced with murine IL-12 recombinant adenoviral vector (AdmIL-12) using the orthotopic 178-2 BMA mouse prostate cancer model. AdmIL-12-transduced macrophages secreted IL-12 in vitro and demonstrated increased surface expression of MHC classes I and II as well as F4/80 antigen compared with uninfected macrophages or those infected with an adenoviral vector containing beta-galactosidase (Adbetagal) in control macrophages. AdmIL-12-transduced macrophages injected into orthotopic 178-2 BMA tumors in vivo induced significant suppression of primary tumor growth and spontaneous lung metastases compared with controls. These antitumor and antimetastatic effects were comparable with those resulting from direct orthotopic delivery of the AdmIL-12 vector. Mice with orthotopic tumors treated with AdmIL-12-transduced macrophages survived significantly longer than controls. Analysis of tumors demonstrated significantly increased infiltration of CD4+ and CD8+ T cells in those injected with AdmIL-12-transduced macrophages compared with controls. Splenocyte-derived cytotoxic natural killer cell activity was enhanced on day 2 after AdmIL-12-transduced macrophage injection, and on day 14, tumor-specific T-lymphocyte activities were increased compared with control, Adbetagal-infected macrophages. Trafficking studies confirmed that intratumorally injected, AdmIL-12-transduced macrophages could migrate to draining lymph nodes. Overall, this novel approach to prostate cancer therapy demonstrates antitumor immune responses that provide effective antimetastatic activities in preclinical studies.

PubMed Disclaimer

Similar articles

• Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.
  Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J, McCurdy MA, Shimura S, Yang G, Timme TL, Thompson TC. Nasu Y, et al. Gene Ther. 1999 Mar;6(3):338-49. doi: 10.1038/sj.gt.3300834. Gene Ther. 1999. PMID: 10435084
• Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
  Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Ren C, Yang G, Goltsov A, Wang H, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Fujita T, et al. Gene Ther. 2007 Feb;14(3):227-36. doi: 10.1038/sj.gt.3302788. Epub 2006 Oct 5. Gene Ther. 2007. PMID: 17024109
• Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
  Saika T, Satoh T, Kusaka N, Ebara S, Mouraviev VB, Timme TL, Thompson TC. Saika T, et al. Cancer Gene Ther. 2004 May;11(5):317-24. doi: 10.1038/sj.cgt.7700709. Cancer Gene Ther. 2004. PMID: 15044961
• CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
  Lubaroff DM, Karan D. Lubaroff DM, et al. Adv Drug Deliv Rev. 2009 Mar 28;61(3):268-74. doi: 10.1016/j.addr.2008.12.005. Epub 2009 Jan 7. Adv Drug Deliv Rev. 2009. PMID: 19166887 Review.
• [Adenovirus-mediated interleukin-12 gene therapy for prostate cancer].
  Nasu Y, Ebara S, Kumon H. Nasu Y, et al. Nihon Rinsho. 2004 Jun;62(6):1181-91. Nihon Rinsho. 2004. PMID: 15206161 Review. Japanese.

Cited by

• The Roles of Tumor-Associated Macrophages in Prostate Cancer.
  Han C, Deng Y, Xu W, Liu Z, Wang T, Wang S, Liu J, Liu X. Han C, et al. J Oncol. 2022 Sep 7;2022:8580043. doi: 10.1155/2022/8580043. eCollection 2022. J Oncol. 2022. PMID: 36117852 Free PMC article. Review.
• Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy.
  Mortezaee K, Majidpoor J. Mortezaee K, et al. Cell Oncol (Dordr). 2022 Jun;45(3):333-353. doi: 10.1007/s13402-022-00667-8. Epub 2022 May 19. Cell Oncol (Dordr). 2022. PMID: 35587857 Review.
• Next-generation cytokines for cancer immunotherapy.
  Xue D, Hsu E, Fu YX, Peng H. Xue D, et al. Antib Ther. 2021 Jun 25;4(2):123-133. doi: 10.1093/abt/tbab014. eCollection 2021 Apr. Antib Ther. 2021. PMID: 34263141 Free PMC article. Review.
• Considering the potential for gene-based therapy in prostate cancer.
  Gregg JR, Thompson TC. Gregg JR, et al. Nat Rev Urol. 2021 Mar;18(3):170-184. doi: 10.1038/s41585-021-00431-x. Epub 2021 Feb 26. Nat Rev Urol. 2021. PMID: 33637962 Review.
• Localized Interleukin-12 for Cancer Immunotherapy.
  Nguyen KG, Vrabel MR, Mantooth SM, Hopkins JJ, Wagner ES, Gabaldon TA, Zaharoff DA. Nguyen KG, et al. Front Immunol. 2020 Oct 15;11:575597. doi: 10.3389/fimmu.2020.575597. eCollection 2020. Front Immunol. 2020. PMID: 33178203 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program